Print 14 September 2015
Key US Patent on electrochemical DNA detection strengthens commercial pathway for Atlas io® System
BATH, England, September 14, 2015 /PRNewswire/ -- Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid 'test and treat' molecular diagnostics company, today announces the granting of a key patent in its intellectual property portfolio.
U.S. Patent No. 9,127,308 covers a key element of Atlas Genetics' proprietary platform, the use of electrochemical methodology to allow rapid and accurate detection of target DNA or RNA contained within a clinical sample. This is the core technology used in the Atlas io® Point of Care Molecular Diagnostic system.
John Clarkson, CEO of Atlas Genetics, said: "The granting of the US patent along with the previous granting of the patent in other key territories, is an important step in the commercialisation of the Atlas Genetics io® system. We are on track to file for regulatory approval in Europe of our first test for Chlamydia around the end of this year."
NOTES TO EDITORS
Atlas Genetics Ltd (http://www.atlasgenetics.com)
Atlas Genetics develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases. The Atlas Genetics io® System uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability. The Company has its head office and R&D facilities near Bath in the UK, with a commercial office in Boston, USA.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
22 September 2017
22 September 2017